MCID: GRM001
MIFTS: 36

Germ Cell and Embryonal Cancer malady

Categories: Cancer diseases, Fetal diseases

Aliases & Classifications for Germ Cell and Embryonal Cancer

Aliases & Descriptions for Germ Cell and Embryonal Cancer:

Name: Germ Cell and Embryonal Cancer 12 14
Neoplasms, Germ Cell and Embryonal 42
Germ Cell and Embryonal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3095
MeSH 42 D009373
UMLS 69 C0027658

Summaries for Germ Cell and Embryonal Cancer

Disease Ontology : 12 A germ cell cancer that is derives from a mixture of germs cells and embryonal cells.

MalaCards based summary : Germ Cell and Embryonal Cancer, also known as neoplasms, germ cell and embryonal, is related to teratoma and trophoblastic neoplasm. An important gene associated with Germ Cell and Embryonal Cancer is POU5F1 (POU Class 5 Homeobox 1), and among its related pathways/superpathways are Wnt Signaling Pathway and Pluripotency and Mesodermal Commitment Pathway. The drugs Cisplatin and Dacarbazine have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and reproductive system

Related Diseases for Germ Cell and Embryonal Cancer

Diseases related to Germ Cell and Embryonal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
id Related Disease Score Top Affiliating Genes
1 teratoma 11.0
2 trophoblastic neoplasm 11.0
3 shoulder and girdle defects-familial intellectual disability syndrome 10.3 KHDC3L NLRP7
4 childhood kidney cell carcinoma 10.3 AFP POU5F1 SOX2
5 severe combined immunodeficiency 10.3 AFP MNX1
6 inhibited male orgasm 10.3 AFP ANO6 POU5F1
7 3-hydroxyacyl-coa dehydrogenase deficiency 10.3 KLF4 POU5F1 SOX2
8 trypanosomiasis, human east-african 10.3 AFP KHDC3L NLRP7
9 agnosia 10.3 CSH1 CSH2
10 ovarian primitive germ cell tumor 10.3 AFP LIN28A
11 mood disorder 10.3 AFP MYC
12 microcephaly, seizures, and developmental delay 10.2 CDKN1C KHDC3L NLRP7
13 3-methylglutaconic aciduria 10.2 AFP CDKN1C MNX1
14 gastrinoma 10.2 AFP TG
15 mutism 10.2 AFP CSH1
16 central nervous system endodermal sinus tumor 10.2 AFP CSH1 CSH2
17 post-surgical hypoinsulinemia 10.2 MYC POU5F1 SOX2
18 flying phobia 10.2 AFP CSH1 CSH2
19 bladder carcinoma in situ 10.2 AFP FUT4
20 kidney disease 10.2 AFP ANO6 POU5F1 TG
21 echolalia 10.2 AFP CSH1 CSH2
22 pediatric liposarcoma 10.2 AFP NANOG POU5F1 SOX2
23 fallopian tube leiomyoma 10.2 AFP FUT4 POU5F1
24 subendocardial myocardial infarction 10.2 AFP NANOG POU5F1 SOX2
25 central nervous system sarcoma 10.2 AFP FUT4 POU5F1
26 blepharochalasis 10.2 AFP CSH1 CSH2
27 central nervous system disease 10.2 AFP FUT4 POU5F1
28 eccrine papillary adenoma 10.2 AFP KRT7
29 breast signet ring cell adenocarcinoma 10.2 KRT7 MYC
30 nutritional deficiency disease 10.1 AFP FUT4
31 angiomyolipoma 10.1 AFP NANOG POU5F1 SOX2
32 esophagus liposarcoma 10.1 AFP POU5F1
33 gastric teratoma 10.1 CSH1 CSH2
34 tick infestation 10.1 CDKN1C CSH1 KHDC3L NLRP7 PAM
35 cellular ependymoma 10.1 AFP KRT7 TG
36 breast mucoepidermoid carcinoma 10.1 KLF4 MYC NANOG POU5F1 SOX2
37 nonossifying fibromyxoid tumor 10.0 AFP KRT7
38 ovarian mucinous cystadenocarcinoma 10.0 CDKN1C CSH1 CSH2
39 malignant ovarian mixed epithelial neoplasm 10.0 AFP CDKN1C KRT7
40 atopic dermatitis 10.0 AFP KRT7 MNX1 POU5F1 SOX2
41 malignant teratoma 10.0 AFP CSH1 CSH2 KRT7
42 malignant pleural solitary fibrous tumor 10.0 AFP KRT7 MYC POU5F1 SOX2
43 intestinal benign neoplasm 10.0 FUT4 KLF4 KRT7
44 toxic encephalopathy 9.9 CDKN1C CSH1 CSH2 KHDC3L NLRP7 PAM
45 persian gulf syndrome 9.9 AFP FUT4 KRT7 MYC
46 toxascariasis 8.2 AFP ANO6 CDKN1C CSH1 CSH2 DIO3

Graphical network of the top 20 diseases related to Germ Cell and Embryonal Cancer:



Diseases related to Germ Cell and Embryonal Cancer

Symptoms & Phenotypes for Germ Cell and Embryonal Cancer

GenomeRNAi Phenotypes related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.47 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.47 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.47 POU5F1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.47 POU5F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.47 KRT7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.47 POU5F1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.47 KRT7 POU5F1 AFP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.47 AFP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.47 POU5F1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.47 AFP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.47 KRT7 POU5F1

MGI Mouse Phenotypes related to Germ Cell and Embryonal Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.23 LIN28A MYC POU5F1 SOX2 AFP DIO3

Drugs & Therapeutics for Germ Cell and Embryonal Cancer

Drugs for Germ Cell and Embryonal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 898)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
3
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
6
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
8
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
15
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
16
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
17
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
19
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
20
Mesna Approved Phase 4,Phase 3,Phase 1,Phase 2 3375-50-6 598
21
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
22
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
23
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
24
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
25
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
26
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
27
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
28
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
29
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
30
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
31
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1 84625-61-6 55283
32
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
33
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
34
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
35
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
36
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
37
Gefitinib Approved, Investigational Phase 4,Phase 1,Phase 2 184475-35-2 123631
38
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
39
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 149647-78-9 5311
40
Nicotine Approved Phase 4 54-11-5 942 89594
41
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
42
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
43
Diazoxide Approved Phase 4,Phase 3,Phase 2 364-98-7 3019
44
Nitroglycerin Approved, Investigational Phase 4,Phase 2 55-63-0 4510
45
Doxazosin Approved Phase 4 74191-85-8 3157
46
Phenoxybenzamine Approved Phase 4 59-96-1 4768
47
Ceritinib Approved Phase 4,Phase 2,Phase 1,Early Phase 1 1032900-25-6
48
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
49
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
50
Palbociclib Approved Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286

Interventional clinical trials:

(show top 50) (show all 4586)
id Name Status NCT ID Phase
1 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177 Phase 4
2 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
3 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
4 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
6 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
7 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
8 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
9 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
10 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
11 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
12 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
13 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
14 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
15 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
16 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
17 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
18 Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors Recruiting NCT01424839 Phase 4
19 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
20 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
21 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
22 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
23 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
24 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
25 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole Recruiting NCT01630954 Phase 4
26 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
27 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
28 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
29 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
30 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
31 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
32 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
33 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
34 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
35 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
36 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
37 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
38 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
39 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
40 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
41 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
42 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
43 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
44 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
45 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
46 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
47 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
48 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
49 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
50 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3

Search NIH Clinical Center for Germ Cell and Embryonal Cancer

Cochrane evidence based reviews: neoplasms, germ cell and embryonal

Genetic Tests for Germ Cell and Embryonal Cancer

Anatomical Context for Germ Cell and Embryonal Cancer

Publications for Germ Cell and Embryonal Cancer

Variations for Germ Cell and Embryonal Cancer

Expression for Germ Cell and Embryonal Cancer

Search GEO for disease gene expression data for Germ Cell and Embryonal Cancer.

Pathways for Germ Cell and Embryonal Cancer

GO Terms for Germ Cell and Embryonal Cancer

Biological processes related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.62 MYC NANOG POU5F1 SOX2
2 response to wounding GO:0009611 9.54 MYC POU5F1 SOX2
3 response to growth factor GO:0070848 9.43 MYC SOX2
4 stem cell population maintenance GO:0019827 9.43 KLF4 LIN28A NANOG
5 hormone biosynthetic process GO:0042446 9.4 DIO3 TG
6 cellular response to cycloheximide GO:0071409 9.16 KLF4 MYC
7 endodermal cell fate specification GO:0001714 9.13 NANOG POU5F1 SOX2
8 somatic stem cell population maintenance GO:0035019 9.02 KLF4 LIN28A NANOG POU5F1 SOX2

Molecular functions related to Germ Cell and Embryonal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.73 KLF4 MNX1 MYC NANOG POU5F1 SOX2
2 sequence-specific DNA binding GO:0043565 9.43 KLF4 MNX1 MYC NANOG POU5F1 SOX2
3 hormone activity GO:0005179 9.33 CSH1 CSH2 TG
4 miRNA binding GO:0035198 8.8 LIN28A POU5F1 SOX2

Sources for Germ Cell and Embryonal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....